Proinflammatory Effect of TWEAK/Fn14 Interaction in Human Retinal Pigment Epithelial Cells

REFERENCES

• Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, Garcia I, Browning JL. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997;272:32401–32410.
   PubMed Web of Science ®Google Scholar
• Lynch CN, Wang YC, Lund JK, Chen YW, Leal JA, Wiley SR. TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem 1999;274:8455–8459.
   PubMed Web of Science ®Google Scholar
• Ho DH, Vu H, Brown SA, Donohue PJ, Hanscom HN, Winkles JA. Soluble tumor necrosis factor-like weak inducer of apoptosis overexpression in HEK293 cells promotes tumor growth and angiogenesis in athymic nude mice. Cancer Res 2004;64:8968–8972
   PubMed Web of Science ®Google Scholar
• Kawakita T, Shiraki K, Yamanaka Y, Yamaguchi Y, Saitou Y, Enokimura N, Yamamoto N, Okano H, Sugimoto K, Murata K, Nakano T. Functional expression of TWEAK in human hepatocellular carcinoma: Possible implication in cell proliferation and tumor angiogenesis. Biochem Biophys Res Commun 2004;318:726–733.
   PubMed Web of Science ®Google Scholar
• Harada N, Nakayama M, Nakano H, Fukuchi Y, Yagita H, Okumura K. Proinflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. Biochem Biophys Res Commun 2002;299:488–493.
   PubMed Web of Science ®Google Scholar
• Wiley SR, Winkles JA. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev 2003;14:241–249.
   PubMed Web of Science ®Google Scholar
• Perper SJ, Browning B, Burkly LC, Weng S, Gao C, Giza K, Su L, Tarilonte L, Crowell T, Rajman L, Runkel L, Scott M, Atkins GJ, Findlay DM, Zheng TS, Hess H. TWEAK is a novel arthritogenic mediator. J Immunol 2006;177: 2610–2620.
   PubMed Web of Science ®Google Scholar
• Wiley SR, Cassiano L, Lofton T, Davis-Smith T, Winkles JA, Lindner V, Liu H, Daniel TO, Smith CA, Fanslow WC. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 2001;15:837–846.
   PubMed Web of Science ®Google Scholar
• Jakubowski A, Browning B, Lukashev M, Sizing I, Thompson JS, Benjamin CD, Hsu YM, Ambrose C, Zheng TS, Burkly LC. Dual role for TWEAK in angiogenic regulation. J Cell Sci 2002;115:267–274.
   PubMed Web of Science ®Google Scholar
• Lynch CN, Wang YC, Lund JK, Chen YW, Leal JA, Wiley SR. TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem 1999;274:8455–8459.
   PubMed Web of Science ®Google Scholar
• Potrovita I, Zhang W, Burkly L, Hahm K, Lincecum J, Wang MZ, Maurer MH, Rossner M, Schneider A, Schwaninger M. Tumor necrosis factor-like weak inducer of apoptosis-induced neurodegeneration. J Neurosci 2004;24:8237–8244.
   PubMed Web of Science ®Google Scholar
• Xu H, Okamoto A, Ichikawa J, Ando T, Tasaka K, Masuyama K, Ogawa H, Yagita H, Okumura K, Nakao A. TWEAK/Fn14 interaction stimulates human bronchial epithelial cells to produce IL-8 and GM-CSF. Biochem Biophys Res Commun 2004;318:422–427.
   PubMed Web of Science ®Google Scholar
• Jin L, Nakao A, Nakayama M, Yamaguchi N, Kojima Y, Nakano N, Tsuboi R, Okumura K, Yagita H, Ogawa H. Induction of RANTES by TWEAK/Fn14 interaction in human keratinocytes. J Invest Dermatol 2004;122:1175–1179.
   PubMed Web of Science ®Google Scholar
• Donohue PJ, Richards CM, Brown SA, Hanscom HN, Buschman J, Thangada S, Hla T, Williams MS, Winkles JA. TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol 2003;23:594–600.
   PubMed Web of Science ®Google Scholar
• Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N, Yamaoka S. TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem 2003;278:36005–36012.
   PubMed Web of Science ®Google Scholar
• Meighan-Mantha RL, Hsu DK, Guo Y, Guo Y, Brown SA, Feng SL, Peifley KA, Alberts GF, Copeland NG, Gilbert DJ, Jenkins NA, Richards CM, Winkles JA. The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. J Biol Chem 1999;274:33166–33176.
   PubMed Web of Science ®Google Scholar
• Perper SJ, Browning B, Burkly LC, Weng S, Gao C, Giza K, Su L, Tarilonte L, Crowell T, Rajman L, Runkel L, Scott M, Atkins GJ, Findlay DM, Zheng TS, Hess H. TWEAK is a novel arthritogenic mediator. J Immunol 2006;177: 2610–2620.
   PubMed Web of Science ®Google Scholar
• Kamata K, Kamijo S, Nakajima A, Koyanagi A, Kurosawa H, Yagita H, Okumura K. Involvement of TNF-like weak inducer of apoptosis in the pathogenesis of collagen-induced arthritis. J Immunol 2006;177:6433–6439.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Burkly LC, Campbell S, Schwartz N, Molano A, Choudhury A, Eisenberg RA, Michaelson JS, Putterman C. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J Immunol 2007;179:7949–7958.
   PubMed Web of Science ®Google Scholar
• Campbell S, Michaelson J, Burkly L, Putterman C. The role of TWEAK/Fn14 in the pathogenesis of inflammation and systemic autoimmunity. Front Biosci 2004;9:2273–2284.
   PubMed Web of Science ®Google Scholar
• Schwartz N, Su L, Burkly LC, Mackay M, Aranow C, Kollaros M, Michaelson JS, Rovin B, Putterman C. Urinary TWEAK and the activity of lupus nephritis. J Autoimmun 2006;27:242–250.
   PubMed Web of Science ®Google Scholar
• Desplat-Jego S, Varriale S, Creidy R, Terra R, Bernard D, Khrestchatisky M, Izui S, Chicheportiche Y, Boucraut J. TWEAK is expressed by glial cells, induces astrocyte proliferation, and increases EAE severity. J Neuroimmunol 2002;133:116–123.
   PubMed Web of Science ®Google Scholar
• Mueller AM, Pedré X, Kleiter I, Hornberg M, Steinbrecher A, Giegerich G. Targeting fibroblast growth factor-inducible-14 signaling protects from chronic relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 2005;159:55–65.
   PubMed Web of Science ®Google Scholar
• Desplat-Jego S, Creidy R, Varriale S, Allaire N, Luo Y, Bernard D, Hahm K, Burkly L, Boucraut J. Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis. Clin Immunol 2005; 117:15–23.
   PubMed Web of Science ®Google Scholar
• Kralisch S, Ziegelmeier M, Bachmann A, Seeger J, Lössner U, Blüher M, Stumvoll M, Fasshauer M. Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis 2008;199:440–444.
   PubMed Web of Science ®Google Scholar
• Nagasawa M, Yi Z, Imashuku S, Nonoyama S, Ogawa K, Okumura K, Mizutani S. Soluble TWEAK is markedly elevated in hemophagocytic lymphohistiocytosis. Am J Hematol 2007;83:222–225.
   Web of Science ®Google Scholar
• Schwartz N, Su L, Burkly LC, Mackay M, Aranow C, Kollaros M, Michaelson JS, Rovin B, Putterman C. Urinary TWEAK and the activity of lupus nephritis. J Autoimmun 2006;27:242–250.
   PubMed Web of Science ®Google Scholar
• Holtkamp GM, Van Rossem M, de Vos AF, Willekens B, Peek R, Kijlstra A. Polarized secretion of IL-6 and IL-8 by human retinal pigment epithelial cells. Clin Exp Immunol 1998;112:34–43.
   PubMed Web of Science ®Google Scholar
• Holtkamp GM, De Vos AF, Peek R, Kijlsta A. Analysis of the secretion pattern of monocyte chemotactic protein-1 (MCP-1) and transforming growth factor-beta 2 (TGF-β2) by human retinal pigment epithelial cells. Clin Exp Immunol 1999;118:35–40.
   PubMed Web of Science ®Google Scholar
• Erger RA, Casale TB. Interleukin-8 is a potent mediator of eosinophil chemotaxis through endothelium and epithelium. Am J Physiol 1995;268:L117–L122.
   Web of Science ®Google Scholar
• Yoshimura T, Robinson EA, Tanaka S, Appella E, Leonard EJ. Purification and amino acid analysis of two human monocyte chemoattractants produced by phytohemagglutinin-stimulated human blood mononuclear leukocytes. J Immunol 1989;142:1956–1962.
   PubMed Web of Science ®Google Scholar
• Taub DD, Proost P, Murphy WJ, Anver M, Longo DL, van Damme J, Oppenheim JJ. Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes. J Clin Invest 1995;95:1370–1376.
   PubMed Web of Science ®Google Scholar
• Elner SG, Elner VM, Jaffe GJ, Stuart A, Kunkel SL, Strieter RM. Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr Eye Res 1995;14:1045–1053.
   PubMed Web of Science ®Google Scholar
• Yoshida A, Yoshida S, Khalil AK, Ishibashi T, Inomata H. Role of NF-kappaB-mediated interleukin-8 expression in intraocular neovascularization. Invest Ophthalmol Vis Sci 1998;39:1097–1106.
   PubMed Web of Science ®Google Scholar
• Cassidy L, Barry P, Shaw C, Duffy J, Kennedy S. Platelet derived growth factor and fibroblast growth factor basic levels in the vitreous of patients with vitreoretinal disorders. Br J Ophthalmol 1998;82:181–185.
   PubMed Web of Science ®Google Scholar
• Kon CH, Occleston NL, Aylward GW, Khaw PT. Expression of vitreous cytokines in proliferative vitreoretinopathy: A prospective study. Invest Ophthalmol Vis Sci 1999; 40:705–712.
   PubMed Web of Science ®Google Scholar
• Limb GA, Little BC, Meager A, Ogilvie JA, Wolstencroft RA, Franks WA, Chignell AH, Dumonde DC. Cytokines in proliferative vitreoretinopathy. Eye 1991;5:686–693.
   PubMedGoogle Scholar
• Wiedemann P. Growth factors in retinal disease: Proliferative vitreoretinopathy, proliferative diabetic retinopathy, and retinal degeneration. Surv Ophthalmol 1992;36:373–384.
   PubMed Web of Science ®Google Scholar
• Briggs MC, Grierson I, Hiscott P, Hunt JA. Active scatter factor (HGF/SF) in proliferative vitreoretinal disease. Invest Ophthalmol Vis Sci 2000;41:3085–3094.
   PubMed Web of Science ®Google Scholar
• Mitamura Y, Takeuchi S, Matsuda A, Tagawa Y, Mizue Y, Nishihira J. Hepatocyte growth factor levels in the vitreous of patients with proliferative vitreoretinopathy. Am J Ophthalmol 2000;129:678–680.
   PubMed Web of Science ®Google Scholar
• Elner SG, Elner VM, Jaffe GJ, Stuart A, Kunkel SL, Strieter RM. Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr Eye Res 1995;14:1045–1053.
   PubMed Web of Science ®Google Scholar
• Aksunger A, Or M, Okur H, Hasanreisoglu B, Akbatur H. Role of interleukin-8 in the pathogenesis of proliferative vitreoretinopathy. Ophthalmologica 1997;211:223–225.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Van Damme JO, Put W, Veckeneer M, Dralands L, Billiau A, Missotten L. Monocyte chemotactic protein-1 in proliferative vitreoretinal disorders. Am J Ophthalmol 1997;123:599–606.
   PubMed Web of Science ®Google Scholar
• Capeans C, De Rojas MV, Lojo S, Salorio MS. C-C chemokines in the vitreous of patients with proliferative vitreoretinopathy and proliferative diabetic retinopathy. Retina 1998;18:546–550.
   PubMed Web of Science ®Google Scholar
• Elner SG, Strieter R, Bian ZM, Kunkel S, Mokhtarzaden L, Johnson M, Lukacs N, Elner VM. Interferon-induced protein-10 and interleukin-8. C-X-C chemokines present in proliferative diabetic retinopathy. Arch Ophthalmol 1998;116:1597–1601.
   PubMedGoogle Scholar
• Yuuki T, Kanda T, Kimura Y, Kotajima N, Tamura J, Kobayashi I, Kishi S. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J Diabetes Complic 2001;15:257–259.
   PubMed Web of Science ®Google Scholar
• Mitamura Y, Takeuchi S, Matsuda A, Tagawa Y, Mizue Y, Nishihira J. Monocyte chemotactic protein-1 in patients with proliferative diabetic retinopathy. Ophthalmologica 2001;215:415–418.
   PubMed Web of Science ®Google Scholar
• Cicik E, Tekin H, Akar S, Ekmekci OB, Donma O, Koldas L, Ozkan S. Interleukin-8, nitric oxide, and glutathione status in proliferative vitreoretinopathy and proliferative diabetic retinopathy. Ophthalmic Res 2003;35:251–255.
   PubMed Web of Science ®Google Scholar
• Lutty G, Merges C, Threlkeld A, Crone S, McLeod S. Heterogeneity in localization of TGF-b in human retina, vitreous, and choroid. Invest Ophthalmol Vis Sci 1993;34:477–487.
   PubMed Web of Science ®Google Scholar
• Tanihara H, Yoshida M, Matsumoto M, Yoshimura N. Identification of transforming growth factor-b expressed in cultured human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 1993;34:413–419.
   PubMed Web of Science ®Google Scholar
• Pfeffer BA, Flanders KC, Guérin CJ, Danielpour D, Anderson DH. Transforming growth factor-b2 is the predominant isoform in the neural retina, retinal pigment epithelium-choroid, and vitreous of the monkey eye. Exp Eye Res 1994;59:323–333.
   PubMed Web of Science ®Google Scholar
• Conner TB, Roberts AB, Sporn MB, Danielpour D, Dart LL, Michels RG, de Bustros S, Enger C, Kato H, Lansing M, Hayashi H, Glaser BM. Correlation of fibrosis and transforming growth factor-b type 2 levels in the eye. J Clin Invest 1989;83:1661–1666.
   PubMed Web of Science ®Google Scholar
• Bochaton-Piallat ML, Kapetanios AD, Donati G, Redard M, Gabbiani G, Pournaras CJ. TGF-β1, TGF-β receptor II, and ED-A fibronectin expression in myofibroblast of vitreoretinopathy. Invest Ophthalmol Vis Sci 2000;41: 2336–2342.
   PubMed Web of Science ®Google Scholar
• Seger R, Krebs EG. The MAPK signaling cascade. FASEB J 1995;9:726–735.
   PubMed Web of Science ®Google Scholar
• Donohue PJ, Richards CM, Brown SA, Hanscom HN, Buschman J, Thangada S, Hla T, Williams MS, Winkles JA. TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol 2003;23:594–600.
   PubMed Web of Science ®Google Scholar
• Hinton DR, He S, Graf K, Yang D, Hsueh WA, Ryan SJ, Law RE. Mitogen-activated protein kinase activation mediates PDGF-directed migration of RPE cells. Exp Cell Res 1998;239:11–15.
   PubMed Web of Science ®Google Scholar
• Jin M, He S, Wörpel V, Ryan SJ, Hinton DR. Promotion of adhesion and migration of RPE cells to provisional extracellular matrices by TNF-α. Invest Ophthalmol Vis Sci 2000;41:4324–4332.
   PubMed Web of Science ®Google Scholar
• Hecquet C, Lefevre G, Valtink M, Engelmann K, Mascarelli F. Activation and role of MAP kinase-dependent pathways in retinal pigment epithelial cells: ERK and RPE cell proliferation. Invest Ophthalmol Vis Sci 2002;43:3091–3098.
   PubMed Web of Science ®Google Scholar
• Liou GI, Matragoon S, Samuel S, Behzadian MA, Tsai NT, Gu X, Roon P, Hunt DM, Hunt RC, Caldwell RB, Marcus DM. MAP kinase and beta-catenin signaling in HGF-induced RPE migration. Mol Vis 2002;8:483–493.
   PubMed Web of Science ®Google Scholar
• Geller SF, Lewis GP, Fisher SK. FGFR1, signaling, and AP-1 expression after retinal detachment: Reactive Müller and RPE cells. Invest Ophthalmol Vis Sci 2001;42:1363–1369.
   PubMed Web of Science ®Google Scholar
• Liou GI, Pakalnis VA, Matragoon S, Samuel S, Behzadian MA, Baker J, Khalil IE, Roon P, Caldwell RB, Hunt RC, Marcus DM. HGF regulation of RPE proliferation in an IL-1beta/retinal hole-induced rabbit model of PVR. Mol Vis 2002;8:494–501.
   PubMed Web of Science ®Google Scholar